Nish Patel, MD
Interventional Cardiology · Miami, FLNPI 1801107867
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Edwards Lifesciences at 52.2% of the total. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 575 payments — averaging $259.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$78K
- Medtronic$28K
- W. L. Gore & Associates, Inc.$22K
- Abbott$12K
- Boston Scientific$2K
- Philips North America LLC$2K
- plus $5K from 27 others
Across 15 payments — averaging $5095.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$76K
What the payments were for
- Consulting fees$74,68350%
- Speaking & faculty fees$24,96317%
- Travel & lodging$27,30418%
- Food & beverage$21,50714%
- Education$6890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 195 | $77,870 |
| Medtronic(2 entities) | 72 | $28,419 |
| W. L. Gore & Associates, Inc. | 29 | $21,671 |
| Abbott | 99 | $11,620 |
| Boston Scientific | 24 | $2,489 |
| Philips North America LLC | 18 | $2,179 |
| Cardiva Medical, Inc. | 6 | $587 |
| ZOLL Circulation Inc | 3 | $425 |
| Abiomed | 14 | $421 |
| Boehringer Ingelheim | 26 | $406 |
| Baylis Medical Company Inc | 2 | $361 |
| Biotronik Inc. | 3 | $337 |
| Penumbra, Inc. | 2 | $313 |
| Cardiovascular Systems Inc. | 14 | $289 |
| Terumo Medical Corporation | 9 | $279 |
| Johnson & Johnson | 8 | $168 |
| Atricure, Inc. | 1 | $166 |
| Novartis | 14 | $162 |
| Cleerly, Inc. | 7 | $160 |
| Inari Medical, Inc. | 1 | $156 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Amgen | 6 | $115 |
| E.r. Squibb & Sons, L.L.C. | 6 | $97 |
| Kestra Medical Technology Services, Inc. | 2 | $82 |
| AstraZeneca | 3 | $49 |
| Chiesi USA, Inc. | 3 | $47 |
| Coopersurgical, Inc. | 1 | $36 |
| Bayer | 1 | $35 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Cordis US CORP. | 1 | $16 |
| Acist Medical Systems, Inc. | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$37,143
- COREVALVE EVOLUT R$21,428
- Product in Development$20,465
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$14,000
- SAPIEN 3 Ultra RESILIA$5,226
- CoreValve Evolut$4,840
- NAVITOR$2,474
- MitraClip$2,194
- Watchman$1,456
- Omnilink Elite vascular stent system$1,213
- AMPLATZER AMULET$1,100
- (9520) IGT Devices Undivided$970
- Mitra Clip system$933
- GORE CARDIOFORM Septal Occluder$599
- IGT Devices Und$551
- Vascular Closure Device$454
- NRG needle$352
- TherOx DS2 Console$348
- Catheter$348
- Downstream Cartridge$348
How this compares
$149,145 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 19 | $29,447 |
| BrilintaTicagrelor | 18 | $14,364 |
| Metoprolol Succinate | 50 | $475 |
| ClopidogrelClopidogrel Bisulfate | 23 | $239 |
| Losartan Potassium | 19 | $114 |
| Amlodipine Besylate | 13 | $110 |
| Atorvastatin Calcium | 22 | $106 |
| Furosemide | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $162 | $29,44719 claims |
| AstraZenecaBrilinta | $49 | $14,36418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Miami
- Eduardo de MarchenaMiami$498K
- Juan ZambranoMiami$173K
- Michael DyalMiami$157K
- Pedro Martinez-ClarkMiami$136K
- Mauricio CohenMiami$129K
- Marquand PattonMiami$112K
- Ramon QuesadaMiami$94K
- Alvaro GomezMiami$71K
- Vinod ChainaniMiami$69K
- Arthur LeeGainesville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.